Want to see IVF full AI Analyst Report?
Top Page
INVO Fertility
(NASDAQ:IVF)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(61.29% Upside)
Action:Reiterated
Date:07/03/26
The score is held back primarily by very weak profitability and persistent cash burn, which elevate funding and sustainability risk despite rapid revenue growth. Technicals are neutral with only mild short-term improvement against a longer-term downtrend, while valuation is constrained by negative earnings and no dividend support. Corporate events provide some offset through clinic consolidation and removal of a Nasdaq compliance overhang, but do not fully mitigate the underlying financial risk.
Positive Factors
Strong Revenue Growth
Sustained multi-year top-line expansion from a small base indicates growing market adoption of INVO’s services and products. Rapid revenue scaling improves the company’s ability to spread fixed costs and supports longer-term operating leverage if growth persists and management contains operating expenses.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow indicates the business is not self-funding growth and will remain dependent on external financing. Over several quarters this elevates dilution and liquidity risk, constraining strategic investments and making the company vulnerable to tighter capital markets or funding delays.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained multi-year top-line expansion from a small base indicates growing market adoption of INVO’s services and products. Rapid revenue scaling improves the company’s ability to spread fixed costs and supports longer-term operating leverage if growth persists and management contains operating expenses.
Read all positive factors
INVO Fertility (IVF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.29M
Dividend YieldN/A
Average Volume (3M)8.28M
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue Growth9.50%
EPS Growth90.44%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-25.17
Shares Outstanding1,786,035
10 Day Avg. Volume24,408,967
30 Day Avg. Volume8,279,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.06
Price to Sales (P/S)0.06
P/FCF Ratio-0.06
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-0.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$10.42M
INVO Fertility Business Overview & Revenue Model
Company Description
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was establi...
How the Company Makes Money
null...
INVO Fertility Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.84M | 6.53M | 3.02M | 822.20K | 4.16M |
| Gross Profit | 2.53M | 2.87M | 1.09M | -28.57K | 4.02M |
| EBITDA | -3.51M | -7.14M | -6.88M | -10.75M | -5.22M |
| Net Income | -23.32M | -9.10M | -8.03M | -10.89M | -6.65M |
Balance Sheet | |||||
| Total Assets | 20.22M | 46.45M | 18.51M | 3.71M | 10.47M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 741.40K | 232.42K | 90.14K | 5.68M |
| Total Debt | 3.40M | 9.90M | 6.30M | 2.27M | 2.12M |
| Total Liabilities | 13.00M | 33.70M | 17.61M | 4.69M | 3.16M |
| Stockholders Equity | 7.22M | 12.75M | 892.83K | -977.61K | 7.31M |
Cash Flow | |||||
| Free Cash Flow | -7.06M | -3.16M | -5.20M | -6.62M | -6.48M |
| Operating Cash Flow | -7.01M | -2.97M | -4.76M | -6.60M | -6.03M |
| Investing Cash Flow | -2.75M | 363.89K | -2.49M | -81.22K | -2.15M |
| Financing Cash Flow | 11.10M | 3.12M | 7.39M | 1.09M | 3.77M |
INVO Fertility Technical Analysis
Negative
0.93
Price Trends
1.63
Negative
2.56
Negative
9.04
Negative
Market Momentum
-0.05
Positive
42.31
Neutral
6.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 1.55, below the 50-day MA of 1.63, and below the 200-day MA of 9.04, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 42.31 is Neutral, neither overbought nor oversold. The STOCH value of 6.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.
INVO Fertility Risk Analysis
INVO Fertility disclosed 60 risk factors in its most recent earnings report. INVO Fertility reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
INVO Fertility Peers Comparison
UnderperformOutperform
Sector (51)
IVF
INVO Fertility
1.28
-101.80
-98.76%
NIVF
NewGenIvf Group
1.33
-550.28
-99.76%
INVO Fertility Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
INVO Fertility Gains Full Control of Alabama Clinic
Positive
Jun 25, 2026
On June 23, 2026, INVO Fertility’s subsidiary INVO Centers acquired 100% of the membership interests in HRCFG, its joint venture partner in the Birmingham, Alabama fertility clinic, for a total consideration of $175,001 structured with minim...
Business Operations and StrategyRegulatory Filings and Compliance
INVO Fertility Updates Investors With New Presentation
Neutral
Jun 16, 2026
On June 16, 2026, INVO Fertility posted a new investor presentation on its website ahead of its appearance at the Planet MicroCap Conference scheduled for June 17, 2026. The presentation outlines the company’s current and long-term operation...
Delistings and Listing ChangesRegulatory Filings and Compliance
INVO Fertility Addresses Nasdaq Compliance Notice and Disclosure
Negative
Apr 29, 2026
On April 23, 2026, INVO Fertility, Inc. received a Nasdaq notice that it was not in compliance with listing rules after failing to timely file its Form 10‑K for the year ended Dec. 31, 2025, a delay the company attributed to the need for add...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.